Back to Search
Start Over
High GFPT1 expression predicts unfavorable outcomes in patients with resectable pancreatic ductal adenocarcinoma
- Source :
- World Journal of Surgical Oncology, World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-8 (2021)
- Publication Year :
- 2020
-
Abstract
- Background Glutamine-fructose-6-phosphate transaminase 1 (GFPT1) is the first rate-limiting enzyme of the hexosamine biosynthesis pathway (HBP), which plays a pivotal role in the progression of pancreatic ductal adenocarcinoma (PDAC). Therefore, we investigated the prognostic significance of GFPT1 expression in patients with resectable PDAC. Methods We analyzed public datasets to compare GFPT1 expression in tumor tissues and normal/adjacent pancreatic tissues. We measured the relative GFPT1 expression of 134 resected PDAC specimens in our institution, using real-time polymerase chain reaction (PCR). Survival was compared between high and low GFPT1 expression groups using Kaplan-Meier curves and log-rank tests. Multivariate analyses were estimated using Cox regression and logistic regression models. Results GFPT1 is generally upregulated in PDAC tissues, according to the analysis of public datasets. The data from our institution shows that high GFPT1 expression was correlated with a high rate of lymph node (LN) metastasis (p = 0.038) and was an independent risk factor for LN metastasis (odds ratio (OR) = 3.14, 95% confidence interval (CI) = 1.42 to 6.90, P = 0.005). High GFPT1 expression was significantly associated with poor overall survival (OS; P = 0.019) in patients with resected PDAC. The multivariable-adjusted hazard ratio (HR) for mortality when comparing patients with high and low GFPT1 expression was 2.54 (95% CI = 1.35 to 4.79, P = 0.004). Conclusions GFPT1 is generally upregulated in PDAC tissue and is associated with a high risk of LN metastasis and an unfavorable outcome in patients with resectable PDAC, suggesting its crucial role in PDAC progression.
- Subjects :
- 0301 basic medicine
Oncology
medicine.medical_specialty
endocrine system diseases
Survival
lcsh:Surgery
Adenocarcinoma
lcsh:RC254-282
Metastasis
03 medical and health sciences
0302 clinical medicine
Surgical oncology
Internal medicine
medicine
Biomarkers, Tumor
Humans
Risk factor
Glutamine-fructose-6-phosphate transaminase 1
Lymph node
Pancreas
Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing)
Proportional hazards model
business.industry
Hexosamine biosynthesis pathway (HBP)
Research
Hazard ratio
lcsh:RD1-811
Odds ratio
lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens
medicine.disease
Prognosis
Confidence interval
Pancreatic Neoplasms
030104 developmental biology
medicine.anatomical_structure
030220 oncology & carcinogenesis
Surgery
business
Carcinoma, Pancreatic Ductal
Subjects
Details
- ISSN :
- 14777819
- Volume :
- 19
- Issue :
- 1
- Database :
- OpenAIRE
- Journal :
- World journal of surgical oncology
- Accession number :
- edsair.doi.dedup.....91bda91bca1f6a00fc3e8ee7273e4e63